Defining Campylobacter and immune response related determinants in the pathogenesis of Guillain-Barré syndrome patients in low-income countries
定义低收入国家格林-巴利综合征患者发病机制中弯曲杆菌和免疫反应相关的决定因素
基本信息
- 批准号:10612447
- 负责人:
- 金额:$ 10.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-08 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAddressAffectAll-Trans-RetinolBangladeshBeliefBiological MarkersBloodBody mass indexC-reactive proteinCampylobacterCampylobacter jejuniCaringClinicalClinical Course of DiseaseDataDevelopmentDiseaseDisease OutcomeEpidemiologyGenetic DeterminismGenomicsGoalsGuillain Barré SyndromeHealthHigh-Throughput Nucleotide SequencingHospitalsIL17 geneImmune responseImmunoglobulin GImmunoglobulin TherapyImmunologic MarkersIncidenceInfectionInfrastructureInterferon Type IIInterleukin-1 betaInterleukin-10Interleukin-4Interleukin-6Intravenous ImmunoglobulinsKnowledgeLiver Function TestsMapsMeasuresMentorsMonitorNetherlandsNeurosciencesNutritionalNutritional statusOutcomePathogenesisPatient CarePatient-Focused OutcomesPatientsPhenotypePoliomyelitisPrediction of Response to TherapyPredictive FactorPrognosisProgram DevelopmentRecommendationRecoveryResearchResearch PersonnelResearch Project GrantsResidual stateRoleSerumSerum AlbuminSeverity of illnessSocioeconomic StatusSupportive careTNF geneTestingTexasTrainingTraining ActivityTreatment outcomeUniversitiesWashingtonZinccareer developmentclinical outcome measuresclinical predictorscohortcostdesigndisabilityeffective therapygenetic variantgenome sequencinggenome wide association studyimprovedindividual patientinsightlow income countrymicrobialmortalityoutcome predictionpathogenpersonalized medicinepotential biomarkerprospectiveresearch and developmentresponseskillsstandard caretreatment responsewhole genome
项目摘要
Project Summary
Since the eradication of poliomyelitis, Guillain-Barré syndrome (GBS) has become a major health
burden in low-income countries. The prognosis of GBS has not improved over the last two
decades. Our group previously showed that the incidence, disease severity and mortality of GBS
are higher in Bangladesh compared to the developed world. The preferred and most effective
treatment for severe GBS is intravenous immunoglobulin (IVIg), yet some patients respond
poorly to this recommended therapy. Little is known about the factors that influence disease
pathogenesis and recovery in patients receiving IVIg therapy in low-income countries. Our
long-term goal is to identify key determinants that predict IVIg treatment response in patients
with GBS from low-income countries. The main hypothesis of the proposed project is that
biological markers, nutritional factors or microbial strain differences may potentially influence the
response of IVIg or clinical course and outcome of patients with GBS in low-income countries.
Our objective is to identify key determinants to measure IVIg treatment responsiveness in
patients with GBS in Bangladesh. Our specific aims will test the following hypotheses: Specific
aim #1: We will identify whether biological markers serve as predictive factors to determine IVIg
treatment response or whether nutritional status affects IVIg treatment response, the clinical
course and GBS disease outcome in a low-income country. Specific aim #2: We will use high-
throughput sequencing to generate and compare the whole genome sequences of
Campylobacter jejuni strains isolated from IVIg-treated and non-treated patients with GBS, in
order to identify the key genetic determinants responsible for disease pathogenesis and
outcomes of IVIg treatment in low-income countries. The research proposed in this career
development application is built upon ongoing, long-standing collaborative efforts between the
icddr,b (Bangladesh), Erasmus University Medical Centre (the Netherlands), the University
of Texas (USA), Washington State University (USA) and the National Institute of Neurosciences
& Hospital (Bangladesh). The goal of this Career Development Program is to strengthen the
skills necessary to become an independent researcher/investigator in host-pathogen
interaction and advanced genomics research.
项目摘要
自消灭脊髓灰质炎以来,格林-巴利综合征(GBS)已成为一种主要的健康
低收入国家的负担。GBS的预后在过去两年中没有改善
几十年我们的研究小组先前表明,GBS的发病率、疾病严重程度和死亡率
与发达国家相比,孟加拉国的死亡率更高。首选和最有效的
严重GBS的治疗是静脉注射免疫球蛋白(IVIg),但有些患者对
这种推荐的疗法效果不佳。人们对影响疾病的因素知之甚少
在低收入国家接受IVIg治疗的患者中,我们
长期目标是确定预测患者IVIg治疗反应的关键决定因素
来自低收入国家的GBS。拟议项目的主要假设是,
生物标志物、营养因素或微生物菌株差异可能潜在地影响
IVIg的反应或低收入国家GBS患者的临床病程和结局。
我们的目标是确定关键的决定因素,以衡量静脉注射免疫球蛋白治疗的反应,
孟加拉国的GBS患者。我们的具体目标将测试以下假设:
目的#1:我们将确定生物标志物是否可作为预测因子来确定IVIg
治疗反应或营养状况是否影响IVIg治疗反应,
低收入国家的病程和GBS疾病结局。具体目标#2:我们将使用高-
通量测序,以生成并比较
从IVIg治疗和未治疗的GBS患者中分离的空肠弯曲杆菌菌株,
为了确定负责疾病发病机制的关键遗传决定因素,
低收入国家的IVIg治疗结果。在这个职业生涯中提出的研究
开发应用程序是建立在持续的,长期的合作努力之间的
icddr,B(孟加拉国)、伊拉斯谟大学医学中心(荷兰)、伊拉斯谟大学
德克萨斯大学(美国)、华盛顿州立大学(美国)和国家神经科学研究所
和医院(孟加拉国)。该职业发展计划的目标是加强
必要的技能,成为一个独立的研究员/调查员在宿主病原体
互动和先进的基因组学研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhahirul Islam其他文献
Zhahirul Islam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhahirul Islam', 18)}}的其他基金
Gut microbiome and regulation on immune responses in Guillain-Barre syndrome: a prospective controlled study
肠道微生物组和吉兰-巴利综合征免疫反应的调节:一项前瞻性对照研究
- 批准号:
10297902 - 财政年份:2021
- 资助金额:
$ 10.43万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 10.43万 - 项目类别:
Research Grant